Based on the promising results of the KEYNOTE-826 trial, the United States Food and Drug Administration sanctioned the amalgamation of pembrolizumab and chemotherapy, with or without bevacizumab, for the primary treatment of recurrent or metastatic cervical cancer in patients with programmed death-ligand 1 (PD-L1)-positivity (with a combined positive score (CPS) ≥1). The gene discussed is CD274; the disease is cervical cancer.